# A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

> **NCT07570823** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 101 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** SCTB35 injection
- **DRUG:** Rituxumab
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT07570823
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-11
- **Final completion:** 2029-04
- **Target enrollment:** 101 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570823, "A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07570823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*